Assembly Bio Exercises 40% US Profit Option With Gilead On HSV

A structured profit-share election by Assembly Biosciences signals a deliberate shift in how development risk and commercial upside are allocated within biotech-pharma antiviral collaborations. The company has formally exercised its option to share 40% of U.S. development costs and profits for its herpes simplex virus (HSV) helicase-primase inhibitor (HPI) program under its existing collaboration agreement with Gilead Sciences, a decision triggered by Assembly Bio's review of Gilead's complete development plan and budget.

Under the collaboration structure, Gilead retains sole responsibility for clinical development and commercialization of the HSV HPI program, which encompasses two investigational compounds: GS-1179 and GS-5366. For supply chain and CMO planning teams, the implication is direct: Gilead controls manufacturing and development execution, while Assembly Bio carries a proportional cost obligation tied to U.S. program activity. Assembly Bio remains eligible for up to $280 million in regulatory and commercial milestones, plus tiered royalties on ex-U.S. net sales ranging from the high single-digits to low teens.

Both parties retain opt-out and conversion rights, which would transition Assembly Bio's economics to up to $330 million in regulatory and commercial milestones alongside tiered royalties on net sales in the high single-digits to low teens range. That optionality introduces a contingent variable in long-term financial modeling for either party's development budget.

On the clinical side, GS-1179 is expected to advance into a Phase 2 trial in participants with recurrent genital herpes by the end of 2026, with potential evaluation as part of a combination strategy with HIV pre-exposure prophylaxis (PrEP). GS-1179 was selected for advancement based on Phase 1b results supporting a once-weekly oral dosing profile and its mechanism targeting the viral helicase-primase enzyme complex, distinct from nucleoside analog therapies currently on the market.

Assembly Bio's cash position is projected to fund operations into 2029, supported in part by a $75 million option continuation payment due from Gilead in Q4 2026, following the third anniversary of the collaboration agreement. That payment provides a near-term financial anchor as the company absorbs its 40% share of U.S. program costs going forward.

The Phase 2 initiation timeline for GS-1179, expected before year-end 2026, will serve as the first measurable checkpoint for whether the profit-share structure delivers on its projected development trajectory.

Source: Assembly Biosciences via GlobeNewswire, September 8, 2026.